PMID- 25744842
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20150306
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 31
IP  - 3
DP  - 2015 Mar
TI  - [Inhibitory effect of emodin on the growth of cervical cancer in 
      tumor-transplanted mice and underlying mechanism].
PG  - 350-4
AB  - OBJECTIVE: To observe the effect of emodin on the growth of transplanted U14 
      cervical cancer cells in mice, and explore its mechanism of anti-tumor. METHODS: 
      The 615-strain mice with U14 cervical cancer cells were randomly divided into 4 
      groups: control group (DMSO), low-dose emodin group (20 mg/kg), high-dose emodin 
      group (40 mg/kg) and cisplatin group (3 mg/kg). Each group included 10 mice. 
      After drug intervention, all mice were sacrificed on day 26 posttransplantation. 
      The volumes and mass of tumors were detected, and tumor inhibition rate was 
      calculated. Microvessel density (MVD) was determined by immunohistochemistry. The 
      mRNA and protein levels of hypoxia inducible factor-1alpha (HIF-1alpha), vascular 
      endothelia growth factor (VEGF) and macrophage migration inhibitory factor (MIF) 
      in tumor tissues were analyzed by real-time quantitative PCR and Western 
      blotting, respectively. Apoptosis index (AI) of tumor tissues was measured by 
      terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), 
      and the Bcl-2 and Bax protein contents were detected by Western blotting. 
      RESULTS: The tumor inhibition rates were 15.83%, 46.92% and 51.22% in low-dose 
      emodin group, high-dose emodin group and cisplatin group, respectively. The tumor 
      inhibition rates were higher in the latter two groups than that in low-dose 
      emodin group. In comparison with control group and low-dose emodin group, the 
      volumes and mass of tumor, MVD as well as the level of HIF-1alpha, VEGF, MIF and 
      Bcl-2 significantly decreased, while the level of AI and Bax significantly 
      increased in high-dose emodin group and cisplatin group. Low-dose emodin had no 
      effects on the above parameters. CONCLUSION: Emodin might suppress the growth of 
      cervical cancer in mice by reducing tumor neovascularization, decreasing MIF 
      expression and promoting tumor cell apoptosis.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Obstetrics and Gynecology, First Affiliated Hospital, University of 
      South China, Hengyang 421001, China.
FAU - Hu, Zecheng
AU  - Hu Z
AD  - Department of Oncological Surgery, First Affiliated Hospital, University of South 
      China, Hengyang 421001, China.
FAU - Chen, Zhongdong
AU  - Chen Z
AD  - Department of Obstetrics and Gynecology, First Affiliated Hospital, University of 
      South China, Hengyang 421001, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (bcl-2-Associated X Protein)
RN  - KA46RNI6HN (Emodin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage
MH  - Apoptosis/drug effects
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Emodin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism
MH  - Mice
MH  - Proto-Oncogene Proteins c-bcl-2/genetics/metabolism
MH  - Uterine Cervical Neoplasms/*drug therapy/genetics/metabolism/physiopathology
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
MH  - Xenograft Model Antitumor Assays
MH  - bcl-2-Associated X Protein/genetics/metabolism
EDAT- 2015/03/07 06:00
MHDA- 2015/07/03 06:00
CRDT- 2015/03/07 06:00
PHST- 2015/03/07 06:00 [entrez]
PHST- 2015/03/07 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Mar;31(3):350-4.